Blood-Based Gene Expression Profiles Models for Classification of Subsyndromal Symptomatic Depression and Major Depressive Disorder by Yi, Zhenghui et al.
Blood-Based Gene Expression Profiles Models for
Classification of Subsyndromal Symptomatic Depression
and Major Depressive Disorder
Zhenghui Yi
1., Zezhi Li
1., Shunying Yu
2, Chengmei Yuan
1, Wu Hong
1, Zuowei Wang
1, Jian Cui
3, Tieliu
Shi
3,4, Yiru Fang
1*
1Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2Department of Genetics, Shanghai
Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 3The Center for Bioinformatics and Institute of Biomedical Sciences, The
College of Life Sciences, East China Normal University, Shanghai, China, 4Shanghai Information Center for Life Sciences, Chinese Academy of Sciences, Shanghai, China
Abstract
Subsyndromal symptomatic depression (SSD) is a subtype of subthreshold depressive and also lead to significant
psychosocial functional impairment as same as major depressive disorder (MDD). Several studies have suggested that SSD is
a transitory phenomena in the depression spectrum and is thus considered a subtype of depression. However, the
pathophysioloy of depression remain largely obscure and studies on SSD are limited. The present study compared the
expression profile and made the classification with the leukocytes by using whole-genome cRNA microarrays among drug-
free first-episode subjects with SSD, MDD, and matched controls (8 subjects in each group). Support vector machines (SVMs)
were utilized for training and testing on candidate signature expression profiles from signature selection step. Firstly, we
identified 63 differentially expressed SSD signatures in contrast to control (P,=5.0E-4) and 30 differentially expressed MDD
signatures in contrast to control, respectively. Then, 123 gene signatures were identified with significantly differential
expression level between SSD and MDD. Secondly, in order to conduct priority selection for biomarkers for SSD and MDD
together, we selected top gene signatures from each group of pair-wise comparison results, and merged the signatures
together to generate better profiles used for clearly classify SSD and MDD sets in the same time. In details, we tried different
combination of signatures from the three pair-wise compartmental results and finally determined 48 gene expression
signatures with 100% accuracy. Our finding suggested that SSD and MDD did not exhibit the same expressed genome
signature with peripheral blood leukocyte, and blood cell–derived RNA of these 48 gene models may have significant value
for performing diagnostic functions and classifying SSD, MDD, and healthy controls.
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Introduction
Depression affects about 10% of the population at some point in
their life and is the leading cause of disability across the world [1].
Lacking specific objective findings, depression is often missed or
undiagnosed [2] and studies have focused on subthreshold
depressive [3–5]. At present, some types of subthreshold
depressive, including dysthymia, minor depression (MinD) and
recurrent brief depression (RBD), are described in the Diagnostic
and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)
[6]. However, approximately two-thirds to three-fourths of all
subthreshold depressive patients with psychosocial functional
impairment did not meet any criteria of DSM-IV [7]. Conse-
quently, the concept of subsyndromal symptomatic depression
(SSD) was introduced by Judd in 1994, which is characterized by
two or more depressive symptoms, but without depressed mood or
anhedonia, lasting for at least 2 weeks accompanied with social
dysfunction, and does not meet the criteria for MDD, dysthymia,
MinD or RBD [7–8]. Convergent evidence has identified that
SSD is a common depressive status that affects different ethnic
populations [7,9–11] and to which we must pay more attention.
However, litter research has been conducted on the biological
basis of SSD.
Although the pathophysioloy of depression spectrum remain
largely obscure, it has been reported that patients with SSD and
MDD have similar family history, and their first-degree relatives
have a high risk of comorbidity of depression and alcohol
dependence, which implies that these two disorders could share
genetic bases
12. Furthermore, several follow-up studies have
suggested that SSD is a transitory phenomena in the depression
spectrum and is thus considered a subtype of depression [10,13–
14]. In addition, previous twin data supported that unipolar
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have different depressive symptoms, may be different subtypes of
depression and have different phenotype at gene expression levels.
With the sequence of the human genome being publicly
available since February 2001, an array of novel research tools,
such as gene expression microarray, have become available that
may yield unbiased, hypothesis-free insight into the pathophysi-
ologic underpinnings of this disorder [16]. The application of
high-throughput gene expression profiling to MDD in humans has
mostly been restricted to postmortem brain tissue, typically
sampled many decades after the critical time frame during which
the initial molecular processes underlying the onset and develop-
ment of disease have occurred, with methodological challenges
including decades of cumulative drug exposure and postmortem
artifacts [17–21]. Convincing evidences indicated that depression
affects the entire organ systems, including endocrinological,
immunological and autonomic nervous systems, through the
interaction between the brain and the body [22]. Circulating
blood comprises a highly complex system that communicates with
every tissue and organ in the body. Peripheral blood cells share
more than 80% of the transcriptome with nine tissues: brain,
colon, heart, kidney, liver, lung, prostate, spleen, and stomach, and
the expression levels of many classes of biological processes have
been shown to be comparable between whole blood and prefrontal
cortex [23–24]. Indeed there is considerable communication
between the immune system and the central nervous system
(CNS). Many cytokine receptors have been located within the
CNS, and interleukin-2 mRNA and T-cell receptors have been
specifically detected in neurons [25]. Lymphocytes also express
several neurotransmitter and hormone receptors, including
dopamine, cholinergic, and serotonergic receptors and glucocor-
ticoid and mineralocorticoid receptors and their chaperones [26].
Lymphocytes are directly influenced by glucocorticoids and
catecholamines, and these two systems are perturbed in MDD
[27]. The circulating blood may act as a ‘‘sentinel tissue’’ that can
reflect states of health or disease within the body. Some studies
successfully discriminated between control subjects and physical
disease patients via detection of the expression of ‘‘tissue-specific’’
genes in circulating blood [28–30]. Blood based gene expression
diagnostics could be applied to the study of psychiatric disorders
for which human brain tissue biopsy samples are unavailable.
Disease development is a systematic and dynamic processes
influenced by environment factors and genetic factors, together.
Computational and systems biology have greatly facilitate the
disease studies from transcriptomes by using microarray technol-
ogy [31]. Based on gene expression profiles, thousands of genes
can be featured simultaneously in different conditions or clinical
phenotypes [32]. Scientists have utilized high-throughput technol-
ogy and computational approach to built disease models and
classify disease state.
With gene features made on microarray accumulated by
technology developing, many psychiatric disorder studies are also
applied by the high-throughput technology with bioinformatics
analysis. Tsuang et.,al have assessed the validity of blood-based
gene expression profiles for the classification of schizophrenia and
bipolar disorder [33]. Segman et.,al found gene expression
signatures that could differentiate between women prone to
postpartum depression [34]. Le-Niculuscu et.,al demonstrated that
peripheral blood gene expression profiles could offer an unex-
pectedly informative insight into brain function and disease state
[35]. Most recently, Spijker et.,al also found that gene expression
profiles could be used as a blood marker of MDD, and careful
independent validation has been carried out to prove their results
[36].
Thus, in order to develop the potential peripheral blood
lymphocytes gene expression signature models which can classify
MDD, SSD, and healthy controls, whole-genome cRNA micro-
array analysis of lymphocytes were performed in this study.
Results
Pathway analysis and GO analysis results for SSD gene
expression signatures
For SSD gene expression signatures, we detected 1,456
differential expressed genes between SSD and healthy controls,
in which 753 genes are up regulated and 703 genes are down
regulated (adjusted p,0.01), which enriched in 47 pathways
(P,0.01). Most of genes involved in several functional related to
signaling pathways, including neuroactive ligand receptor inter-
action, JAK and STAT signaling pathway, G protein signaling,
calcium signaling pathway, insulin signaling pathway, GNRH
signaling pathway, Wnt signaling pathway and MAPK signaling
pathway etc. Cellular communication and cell structure organi-
zation were also important in SSD process, such as apoptosis, cell
adhesion molecules, tight junction, focal adhesion. The DEG also
act in several biosynthesis and metabolism pathways, like oxidative
phsphorylation, metabolism of xenobiotic by cytochrome P450,
purine metabolism, glycerlipid metabolism, glycan structures
biosynthesis, glycerolipid metabolism, starch and sucrose metab-
olism. We also found that SSD signatures participate in immunity
process, antigen processing, leukocyte transendothelial migration,
natural killer cell mediated cytototoxicity and cytokine-cytokine
receptor interaction (Figure 1A). GO analysis indicate that SSD
gene signatures correlate with cerebellar cortex morphogenesis,
cerebellar granular layer development, hydrolase activity, GTPase
and ATPase activity, S phase and M phase of mitotic cell cycle and
tissue regeneration, etc. (Figure 1B).
Pathway analysis and GO analysis results for MDD gene
expression signatures
Based on pre-processed microarray profile, we identified 149
differential genes between MDD patients and controls with 95
upregulated and 54 down-regulated (adjusted P,0.01), 20 of
which were identified between SSD and control. These differential
genes enriched in 53 pathways, 2 of which also were identified in
SSD. Signaling pathways active in MDD include activation of
ATR in response to replication stress, NRIF signals cell death from
the nucleus, fas signaling pathway, p53-Independent G1/S DNA
damage checkpoint and Nicotinamide salvaging, and EGF
signaling pathway etc. We noticed that many MDD signatures
involves several immunity process, such as T cell receptor signaling
pathway and JNK signaling in the CD4+ TCR pathway, IL2-
mediated signaling events, IL1 signaling and IL6-mediated
signaling events and Calcium signaling in the CD4+ TCR
pathway and TCR signaling in CD4+ T cells. In MDD subjects,
more biosynthesis and metabolism pathway are identified,
involveing Vitamin B5 (pantothenate) metabolism, coenzyme A
biosynthesis and metabolism of water-soluble vitamins and
cofactors. Comparing with former results of SSD signatures, we
found that several pathways were shared in MDD and SSD
process, including cell cycle controls and Cell Cycle Checkpoints,
like G2/M Checkpoints and Wnt signaling. We noticed that
MDD-specific functions or pathways compared with SSD were
activation of ATR pathway in response to replication stress, NRIF
signals cell death from the nucleus, fas signaling pathway,
immunity pathway about IL2 signaling events mediated by
PI3K and IL1 singaling events. Meanwhile, SSD-specific pathways
contain cytokine-cytokine receptor interaction, GPCRDB class A
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receptor interaction, calcium signaling pathway, breast cancer
estrogen signaling pathway, purine metabolism, insulin signaling
pathway, cell adhesion molecules and Toll like receptor signaling
pathway(Figure 1C). Alternatively, GO analysis for MDD signatures,
29 of which also were identified in SSD, convinced us that most
significant functions (P,0.01) are active in immunity reactions
involving pro-B cell differentiation, negative regulation of antigen
processing, positive regulation of leukocyte migration and plasmin-
ogen activation. Other functions of these genes involve engulfment of
apoptotic cell, fibrinogen binding, lymphoid progenitor cell differen-
tiation and immunoglobulin V(D)J recombination and mitotic cell
cycle controls (S phase), DNA ligation involved in DNA repair and
somatic cell DNA recombination, etc. al. (Figure 1D).
Gene expression profiles for classification of
subsyndromal symptomatic depression and major
depressive disorder
In order to filter out most of false positives and select most
potential biomarkers, we applied strict threshold on the same pair-
wise comparisons among SSD, MDD and controls, and identified
63 differentially expressed SSD signatures in contrast to controls
(adjusted P,=1.0E-4) and 30 differentially expressed MDD
signatures in contrast to controls (adjusted P,=5.0E-4), respec-
tively. Then, 123 gene signatures were identified with significantly
differential expression level between SSD and MDD (adjusted
P,=1.0E-4). Unsupervised hierarchal clustering analysis by using
Euclidean distance and complete linkage clustering method was
conducted on three more potential groups of DEGs. The results
showed clearly that genes differentially expressed in the peripheral
blood lymphocytes were capable of differentiating MDD group,
SSD group and healthy controls, separately (Fig. 2 A, B, C).
To evaluate the predictive performances of SSD and MDD
signatures respectively, we utilized SVM with Linear Kernel to
build disorder models. For 63 SSD signatures (adjusted P,=1.0E-
4), total instances (8 SSD and 8 control instances, respectively) were
correctly classified. Similarly, for 30 MDD signatures (adjusted
P,=5.0E-4), and 123 DEGs signatures (adjusted P,=1.0E-4) can
also clearly classified 8 MDD and 8 SSD instances.
For SSD gene signatures, we detected 1,456 differential
expressed genes between SSD and control; For MDD gene
signatures, we identified 149 differential genes between MDD
patients and controls d. Among these genes, there are only 20
different genes between SSD and MDD.
Furthermore, in order to conduct priority selection for biomark-
ers for SSD and MDD together, we selected top gene signatures
from each group of pair-wise comparison results, and merged the
signaturestogethertogeneratebetterprofilesusedforclearlyclassify
SSD and MDD states in the same time. In details, we tried different
combination of signatures from top ranked signatures in the three
pair-wise compartmental results and finally determined 48 gene
expression signatures (Table 1). To maintain the robustness of SSD-
MDD disorder model, the predictive power was evaluated using
cross validation, which randomly took 9/10 samples used for
training and remaining 1/10 as internal testing validation.
When 54 probesets (48 genes) were chosen as biomarkers, we
obtained the best predictive performances with 100% accuracy
and 100% TPR (leave-one-off validation). Leave-one-off valida-
tion refers to that we used n-1 sample to train model and used
another sample to test the model. Total 24 MDD, SSD and
control samples were separated into train and test profiles in 24
Figure 1. Functional annotation of the DEGs in SSD and MDD. (A) and (C) Pathway analysis of SSD-associated and MDD-associated genes
respectively. The y-axis shows the KEGG Pathway terms, and the x-axis shows the enrichment significance P-values for the top 10 enriched Pathway
terms. (B) and (D) GO analysis of SSD-associated and MDD-associated genes respectively. The y-axis shows the GO terms, and the x-axis shows the
enrichment significance P-values for the top 10 enriched GO terms. Term GO:0004719 remarks the function of protein-L-isoaspartate (D-aspartate) O-
methyltransferase activity. MDD: Major depression disorder; SSD: Subsyndromal symptomatic depression.
doi:10.1371/journal.pone.0031283.g001
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we collected the predictions for each sample, and obtained 100%
predictive performance (Table 2).
Then, we interrogated the pathways and biological functions
about these mostly potential biomarkers for MDD and SSD,
together. Pathway analysis demonstrates that the potential 48 gene
biomarkers involved in insulin signaling pathway, signaling by
NGF, ErbB signaling pathway, neurotrophin signaling pathway,
cell surface interactions at the vascular wall, NRAGE signals death
through JNK, Rho GTPase cycle, and G alpha signaling pathway
(P value,0.05) (Table 3). Also, GO analysis shows consistency
with pathway analysis results. Besides, PURA and TERF2 both
function about telomeric DNA binding and single strand DNA
binding, and DNA replication. SLC16A3 and CTNS act in the
directed movement of carboxylic acids into, out of, within or
between cells. FGD3 and KALRN participate in Stimulates the
exchange of guanyl nucleotides by a GTPase. Under normal
cellular physiological conditions, the concentration of GTP is
higher than that of GDP, favoring the replacement of GDP by
GTP in association with the GTPase. Also, FGD3, KALRN and
RHOQ involve in Rho GTPase cycle. Other signatures also
correlated with Cell death signalling via NRAGE, NRIF and
NADE, Jak-STAT signaling pathway, B cell receptor signaling
pathway, and p75 NTR receptor-mediated signaling (Table 4).
De novo cis-Regulatory element analysis results for
candidate biomarkers of MDD and SSD
In order to investigate how the signatures for classifying three
groups are regulated, we analyzed the cis-regulaotry elements co-
occurring on the promoters of these genes. In details, STAT1 and
STAT2 factor’ binding motifs were detected on five MDD
signatures’ promoters (e.g. BDNF, MYB, THBS1, SORBS1, and
SH3BGRL). In addition, we identified SRF binding motif on three
gene promoters (e.g. THBS1, EGR1 and PODN). For SSD
signatures, we identified transcriptional factor SREBP1 was
correlated with eleven SSD signature genes (GNAS, MLL5,
TOM1L1, DLGAP4, PTMA, NF1, ATP2B2, UNC13D, PDP2,
CORO1A, and INPP4A). Most of these transcriptional factors are
related with depression disorders as discussed below.
Discussion
To our knowledge, this is the first study to compare the
expression profile and make the classification with the leukocytes
by using whole-genome cRNA microarrays among patients with
SSD, major depressive disorder (MDD) and controls. We found
that SSD and MDD had different blood-based gene expression
signature, and the differential expressed genes of SSD were about
10 times of MDD, but there are only 20 overlapping differential
expressed genes between SSD and MDD. Pathway analysis for
SSD gene signatures showed that differential expressed genes
enriched in 47 pathways, and most pathways were involved in
regulation of DNA replication, IL2 signaling events mediated by
STAT5, and Wnt signaling pathway, etc. For MDD gene
signatures, the results of pathway analysis suggested that
differential expressed genes enriched in 53 pathways, 2 of which
also were identified in SSD, including MAPK signaling pathway
and Wnt signaling pathway. Although the relationship between
SSD and MDD is unclear, previous follow-up studies have showed
Figure 2. Biomarkers differentiation efficiency among MDD group, SDD group and HC. (A) Complete linkage clustering analysis with 16
samples using 30 biomarkers under the criteria of adjusted.P,=5E-4 between MDD and HC. (B) Complete linkage clustering analysis with 16 samples
using 63 biomarkers under the criteria of adjusted.P,=1E-4 between SSD and HC. (C) Complete linkage clustering analysis with 16 samples using
123 biomarkers under the criteria of adjusted.P,=1E-4 between SSD and MDD. MDD: Major depression disorder; SSD: Subsyndromal symptomatic
depression; HC: Healthy controls.
doi:10.1371/journal.pone.0031283.g002
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Probe Gene Symbol SSD vs. HC MDD vs. HC MDD vs. SSD
FC (adjusted p,0.0001) FC (adjusted p,0.0005) FC (adjusted p,0.0001)
202123_s_at ABL1 0.741304049 1.071540957 1.445481053
203142_s_at AP3B1 0.785262839 1.163049415 1.481095700
212645_x_at BRE 0.622357591 0.989984919 1.590701125
213986_s_at C19orf6 0.479842399 1.004084118 2.092528964
200723_s_at CAPRIN1 0.716725182 1.016565288 1.418347389
200952_s_at CCND2 0.432720956 0.982303164 2.270061461
211188_at CD84 0.521512199 0.928367596 1.780145501
1554339_a_at COG3 0.357536796 0.991125007 2.772092322
204925_at CTNS 0.650193383 0.962500784 1.480330023
201275_at FDPS 1.312775229 0.929569711 0.708095103
1555407_s_at FGD3 0.459952028 1.051968262 2.287126038
204867_at GCHFR 1.417582619 1.159141932 0.817689154
1554356_at GINS4 0.943637323 0.557990569 0.591318885
204553_x_at INPP4A 0.727800115 0.966193858 1.327553869
206078_at KALRN 2.421891723 0.831693595 0.343406597
225642_at KTI12 1.032925752 1.217211291 1.178411218
1565406_a_at LHX9 3.616566285 4.484406509 1.239962483
212535_at MEF2A 0.739248358 0.967245398 1.308417379
1557172_x_at NEK8 1.496780327 0.827608072 0.552925541
200875_s_at NOP56 1.361209547 0.941029044 0.691318281
202647_s_at NRAS 0.706715422 1.122941274 1.588958217
216422_at PA2G4 2.674676802 2.203654734 0.823895707
1557777_at PDE6B 0.318473762 0.978799188 3.073406053
1554508_at PIK3AP1 0.651835063 1.287048315 1.974499972
1567214_a_at PNN 1.276179391 0.992966418 0.778077462
204842_x_at PRKAR2A 1.453510563 0.905753493 0.623148891
209685_s_at PRKCB 1.459071747 1.094764429 0.750315693
204021_s_at PURA 2.021380345 1.105199279 0.546754737
212120_at RHOQ 0.618194385 0.928620496 1.502149676
200089_s_at RPL4 1.238633645 0.961953034 0.776624337
226923_at SCFD2 0.794178375 0.719803168 0.906349494
1552812_a_at SENP1 0.675377839 1.137970532 1.684939105
204019_s_at SH3YL1 0.757933305 0.658471379 0.868772193
202855_s_at SLC16A3 0.504525282 1.003367055 1.988734935
1552792_at SOCS4 0.424980413 0.877342521 2.064430488
205026_at STAT5B 0.497586762 0.987611266 1.984802134
205520_at STRN 0.476780581 1.116717124 2.342203456
203611_at TERF2 0.799885457 1.051562728 1.314641639
200804_at TMBIM6 1.362494303 1.173043411 0.860952892
212282_at TMEM97 0.633075615 0.722453817 1.141180927
201796_s_at VARS 0.539085621 1.680791788 3.117856841
1552737_s_at WWP2 0.324152671 0.963600812 2.972675826
225072_at ZCCHC3 1.512482696 3.071112709 2.030510971
1554769_at ZNF785 1.899359591 0.781703552 0.411561641
1553704_x_at ZNF791 1.393734556 0.892755221 0.640548961
202848_s_at GRK6 0.543637323 0.357990569 0.658509918
206382_s_at BDNF 0.407145759 0.358749192 0.881132014
202343_x_at COX5B 0.557536796 0.391125007 0.701523217
MDD: Major depression disorder; SSD: Subsyndromal symptomatic depression; HC: Healthy controls.
doi:10.1371/journal.pone.0031283.t001
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phenomenon in depression spectrum with a high likelihood of
transition to MDD [10,12–13]. It indicates that the genes
involving in these two pathways maybe point to pathogenetically
relevant underlying molecular processes of depression.
Genetic manipulation of the MAPK pathway, one of the
neurotrophin signaling pathways, has received much attention,
which postulated that the dysfunction of this pathway played a key
role in the pathophysiology of mood disorders [37], especially in
depression-like behavior [38]. Previous data also have shown that
acute systemic blockade of MAPK signaling contributes to a
depressive-like phenotype and blocks actions of antidepressants in
animal models of depression [39].
Wnt signaling pathways have been implicated in various
physiological functions, such as cell fate determination, cell and
tissue polarity, synaptogenesis, dendritic morphogenesis, and axon
remodeling. Moreover, abnormal Wnt signaling has been
implicated in mood disorder. The relationship between Wnt
signaling pathway genes and mood disorders has been reported in
several genetic association studies. A study showed that alteration
of hippocampal microRNA levels following chronic treatment
with mood stabilizers is caused by effectors in the canonical Wnt
signaling pathway. Gene expression-profiling of hippocampal
subfields has also revealed altered expression of several genes
related to Wnt signaling in bipolar disorder patients. Another
study supports that the canonical Wnt signaling pathway and
related substrates play a role in MDD. Wnt signaling pathway also
has been considered relevant to the antidepressant effects, and
Wnt2 expression and signaling is a common target of antidepres-
sants and that increased Wnt2 is sufficient to produce antidepres-
sant effects.
Moreover, patients with MDD have depressed mood or
anhedonia but SSD have not, so differential expression of genes
involving in other 51 pathways in MDD may be correlate with the
underlying pathological mechanism of the symptom of depressed
mood or anhedonia. Our unsupervised hierarchal clustering
analysis showed obviously that each disease state exhibited a
unique expressed genome signature except the genes involving in
MAPK and Wnt pathways, which suggesting that these two
diseases may be two different phenotypes in depression spectrum
by respective gene signatures. Furthermore, genes differential
expression among SSD group, MDD group, and healthy controls
allowed us to discriminate among these three groups. It suggested
that blood-derived RNA may potentially be used as a diagnostic
tool for SSD and/or MDD, as long as the correct subsets of genes
are employed. Blood profiling may also allow identification of
differentially expressed genes that are involved in the pathophys-
iology of these disorders. To select the most potential biomarkers
for differentiating these three groups, we combined top differential
expressed genes from each set of gene expression signatures, then
trained and tested the multiple combinatorial gene signatures from
pair-wise comparison groups by using support vector machine
classifier. Finally 48 gene expression signatures were determined.
Samples can be grouped together according to the similarity of the
expression levels of these 48 genes which suggested that different
levels of gene expression may reflect different disease states.
Among differential genes, BDNF, COX5B, GRK6 are the most
significantly differential genes.
We comprehensively analyzed gene functions and pathway for
the candidate biomarkers of SSD and MDD and found that
potential biomarkers act in some pathways which have been found
associated with function of CNS and implicated in depression,
including insulin signaling pathway, signaling by NGF, ErbB
signaling pathway and neurotrophin signaling pathway. We also
found most of them were not reported the relationship with
depression, such as cell surface interactions at the vascular wall,
NRAGE signals death through JNK, Rho GTPase cycle, and G
alpha signaling pathway, etc. al.
Some studiesshowed thattherewas a positiveassociation between
depressive disorder and insulin resistance due to dysregulation of
insulin secretion or insulin receptor signaling. Otherwise, various
functions for insulin receptor signaling in the brain have been
suggested in normal neurophysiology, such as insulin receptor
signaling maybe play a important role in synaptic plasticity and
cognitive function,and several lines of work in both laboratory
animals and humans suggest that when neurons in cognitive brain
regions such as the hippocampus and cerebral cortex do not make
enough insulin or cannot respond to insulin properly, everything
from very mild memory loss to severe neorodegenerative diseases
can result. Dysregulation of insulin secretion or insulin receptor
signaling has also been reported in serious mental illnesses, such as
Alzheimer’s disease. Patients with depression also have some
cognitive function problems and maybe have differential expression
of genes involving in insulin signaling pathway.
It has been suggested that neuronal atrophy or destruction in
the hippocampus and cortex is involved in the pathogenesis of
depression. The neurotrophin systems modulate neuronal plastic-
ity, inhibit cell death cascades and increase cell survival proteins
that are responsible for proliferation and maintenance of central
nervous system neurons. Thus the dysregulation of the neurotro-
Table 2. Predictive performances of disorder model.
Biomarker
Number Class label TPR FPR Accuracy ROC area
30(10*3) HC 1 0.063 0.889 0.969
SSD 0.875 0.063 0.875 0.883
MDD 0.875 0 1 0.969
Weighted 0.917 0.042 0.921 0.94
45(15*3) HC 1 0.063 0.889 0.969
SSD 0.875 0 1 0.965
MDD 1 0 1 1
Weighted 0.958 0.021 0.963 0.978
54(18*3) HC 1 0 1 1
SSD 1 0 1 1
MDD 1 0 1 1
Weighted 0.958 0.021 0.963 0.978
60(20*3) HC 1 0.063 0.889 0.969
SSD 0.875 0 1 0.965
MDD 1 0 1 1
Weighted 0.958 0.021 0.963 0.978
75(25*3) HC 1 0.063 0.889 0.969
SSD 0.875 0 1 0.969
MDD 1 0 1 1
Weighted 0.958 0.021 0.963 0.979
90(30*3) HC 1 0.063 0.889 0.969
SSD 0.875 0 1 0.973
MDD 1 0 1 1
Weighted 0.958 0.021 0.963 0.98
MDD: Major depression disorder; SSD: Subsyndromal symptomatic depression;
HC: Healthy controls.
doi:10.1371/journal.pone.0031283.t002
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signaling by NGF (nerve growth factorA) and neurotrophin
signaling pathway, may be involved in the pathophysiology of
depression.
Transgenic mouse experiments have confirmed that the block of
erbB signaling pathway will result in the change of OL number
and morphology, reducing the thickness of myelin and the
transmission rate of CNS axons [40]. The abnormal expression
of ERBB (epidermal growth factor receptor, EGFR, epidermal
growth factor receptor) signaling pathway can lead to oligoden-
drocytes (OL) abnormalities, which results in dopaminergic
dysfunction, and it may be associated with depression [41–42].
The results of analysis of the cis-regulaotry elements co-
occurring on the promoters of these genes showed that STAT1
and STAT2 factors were detected on five MDD signatures’
promoters (e.g. BDNF, MYB, THBS1, SORBS1, and
SH3BGRL). Especially, STAT1 mediates the autoimmune and
inflammatory functions, and STAT2 mediates the virus protection
function. From previous investigation about the immune cell
specificity of activation programs induced by a major component
of cell-mediated immunity, the transcriptional activators STAT1
were significantly induced in CD4+ and CD8+ T cells, B cells and
monocytes [43]. Depression phenotypes are also correlated with
immunity reactions reflected from blood transcriptomes [44]. In
addition, we identified SRF binding motif on three gene promoters
(e.g. THBS1, EGR1 and PODN). Up to now, there was no study
about the relationship between SRF binding motif and depression.
For SSD signatures, we identified transcriptional factor SREBF1
was correlated with eleven SSD signature genes (GNAS, MLL5,
TOM1L1, DLGAP4, PTMA, NF1, ATP2B2, UNC13D, PDP2,
CORO1A, and INPP4A). Several studies have reported the
importance of SREBF1 and SREBF2 factors in the lipid
biosynthesis and their possible involvement in antipsychotic drug
effects and the genetic variants of SREBF1 and/or SREBF2 could
affect schizophrenia susceptibility [44–45]. HapMap-based associ-
ation study in a large German sample identified association between
schizophrenia and five markers in SREBF1 and five markers in
SREBF266. Additionally, scientists have demonstrated in glial cell
lines that antipsychotic drugs induce the expression of genes
involved in cholesterol and fatty acids biosynthesis through
activation of the sterol regulatory element binding protein (SREBP)
transcription factors, encoded by the sterol regulatory element
binding transcription factor 1 (SREBF1) and sterol regulatory
element binding transcription factor 2 (SREBF2) genes [45].
The results presented were limited by a modest sample size and
required more samples to replicate. Quantitative reverse tran-
scription-polymerase chain reaction were required to exam the
expression levels of 48 genes, which were found differentially
expressed in our pilot study, in a larger sample of SSD and MDD.
Additional studies were required to further explore the roles of
these 48 genes in pathophysiology of SSD and MDD.
In conclusion, our study demonstrated that SSD and MDD
exhibited a unique expressed genome signature with peripheral
blood leukocyte, and blood cell–derived RNA may have significant
Table 3. Mostly potential pathways of disorder model biomarker.
Gene Set Name
Genes in Gene
Set (K) Description
Genes in
Overlap (k) k/K p value
KEGG insulin signaling pathway 137 Insulin signaling pathway 4 0.0292 1.15E-02
KEGG chronic myeloid leukemia 73 Chronic myeloid leukemia 3 0.0411 1.15E-02
Reactome signaling by NGF 215 Genes involved in Signalling by NGF 5 0.0233 1.20E-02
Reactome myogenessis 29 Genes involved in MyoGenessis 2 0.069 1.49E-02
KEGG ERBB signaling pathway 87 ErbB signaling pathway 3 0.0345 1.83E-02
Reactome down stream signal transduction 35 Genes involved in Down-stream signal transduction 2 0.0571 2.12E-02
Reactome cell surface interactions at the
vascular wall
94 Genes involved in Cell surface interactions at the
vascular wall
3 0.0319 2.25E-02
Reactome NRAGE signals death through
JNK
47 Genes involved in NRAGE signals death through JNK 2 0.0426 3.68E-02
Reactome RHO GTPase_cycle 124 Genes involved in Rho GTPase cycle 3 0.0242 4.55E-02
Reactome G Alpha 12_13 signalling events 54 Genes involved in G alpha (12/13) signalling events 2 0.037 4.73E-02
KEGG neurotrophin signaling pathway 126 Neurotrophin signaling pathway 3 0.0238 4.74E-02
Biocarta PPARA pathway 58 Mechanism of Gene Regulation by Peroxisome
Proliferators via PPARa(alpha)
2 0.0345 5.38E-02
KEGG acute myeloid leukemia 60 Acute myeloid leukemia 2 0.0333 5.71E-02
Reactome cell death signaling via NRAGE
NRIF and NADE
61 Genes involved in Cell death signalling via NRAGE,
NRIF and NADE
2 0.0328 5.88E-02
Reactome signaling by PDGF 64 Genes involved in Signaling by PDGF 2 0.0312 6.40E-02
KEGG JAK_STAT signaling pathway 155 Jak-STAT signaling pathway 3 0.0194 7.80E-02
KEGG B_cell receptor signaling pathway 75 B cell receptor signaling pathway 2 0.0267 8.43E-02
Reactome P75_NTR receptor mediated
signalling
82 Genes involved in p75 NTR receptor-mediated
signalling
2 0.0244 9.81E-02
KEGG chemokine signaling pathway 190 Chemokine signaling pathway 3 0.0158 1.24E-01
Reactome TRKA signaling from the plasma
membrane
103 Genes involved in TRKA signalling from the plasma
membrane
2 0.0194 1.43E-01
doi:10.1371/journal.pone.0031283.t003
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biomarkers in SSD and MDD.
Materials and Methods
The study was conducted at the Division of Mood Disorders,
Shanghai Mental Health Center, Shanghai Jiao Tong University
School of Medicine between Jan 2007 and Dec 2009. Outpatients
were recruited from the clinic and ward of Shanghai Mental
Health Center. All procedures were reviewed and approved by
Institutional Review Boards of Shanghai Mental Health Center.
Written informed consent was obtained from each subject before
any study-related procedures were performed.
Subjects
Inclusion criteria for SSD group were: two or more depressive
symptoms for at least 2 weeks with social dysfunction but without
depressed mood or anhedonia, and having a total score of 17-item
Hamilton Rating Scale for Depression (HRSD-17) from 8 to 16.
Patients were included into MDD group who met DSM-IV criteria
for MDD and had the total score of HRSD-17 $17. Patients were
excluded if they had substance dependence, severe medical illness,
organic brain disease, pregnancy. Healthy control subjects have a
score 7 or lower on the HRSD-17, and did not have any major Axis
I disorders (including substance dependence, psychotic disorders,
mood disorders and anxiety disorders), family history of mental
disorder or severe physical diseases (hypertension, diabetes, cancer).
For the gene expression microarray analysis, this study enrolled
eight drug-free Chinese Han patients with their first episode of
subsyndromal symptomatic depression, eight previously untreated
patients presenting with their first episode of major depression
disorder, and eight healthy controls. All groups were matched with
sex and age (shown in Table 5).
All subjects were screened by the Structured Clinical Interview
for DSM-IV (SCID) and assessed through HRSD-17 score by two
experienced psychiatrists (inner coherence, Kappa=0.87).
Peripheral blood lymphocytes collection and RNA
processing
Total 20 ml venous peripheral blood from fasting patients and
healthy controls were collected during 7am to 9am. Peripheral
blood lymphocytes were separated by Ficoll gradient centrifuga-
tion using Ficoll-PlaqueTM Plus (GE, Sweden) [46].Total RNA
was extracted from lymphocytes using Trizol reagent (Invitrogen)
according to the manufacturer’s protocol. RNA quality was
determined by Nanodrop ND-1000 (Nanodrop Technologies,
Wilmington, DE) and degradation of mRNA was assessed by
denaturing agarose gel electrophoresis and evaluated the sharpness
of 28 S and 18 S rRNA bands.
Microarray data pre-processing
24 samples were profiled on affymetrix U133 Plus2.0 GeneChip
oligonucleotide arrays (Affymetrix, Santa Clara, CA), which is
Table 4. Mostly potential GO functions of disorder model biomarker.
Gene Set Name
Genes in Gene
Set (K) Description
Genes in
Overlap (k) k/K p value
Telomeric DNA binding 10 Genes annotated by the GO term GO:0042162. Interacting
selectively with telomere-associated DNA, usually
characterized by highly repetitive sequences.
2 0.2000 1.58E-03
Single stranded DNA binding 34 Genes annotated by the GO term GO:0003697. Interacting
selectively with single-stranded DNA.
2 0.0588 1.80E-02
DNA replication 101 Genes annotated by the GO term GO:0006260. The process
whereby new strands of DNA are synthesized. The template
for replication can either be an existing DNA molecule or RNA.
3 0.0297 2.32E-02
Carboxylic acid transport 41 Genes annotated by the GO term GO:0046942. The directed
movement of carboxylic acids into, out of, within or between
cells. Carboxylic acids are organic acids containing one or
more carboxyl (COOH) groups or anions (COO-).
2 0.0488 2.56E-02
Guanyl nucleotide exchange
factor activity
42 Genes annotated by the GO term GO:0005085. Stimulates the
exchange of guanyl nucleotides by a GTPase. Under normal
cellular physiological conditions, the concentration of GTP is
higher than that of GDP, favoring the replacement of GDP by
GTP in association with the GTPase.
2 0.0476 2.67E-02
Organic acid transport 42 Genes annotated by the GO term GO:0015849. The directed
movement of organic acids, any acidic compound containing
carbon in covalent linkage, into, out of, within or between
cells.
2 0.0476 2.67E-02
DNA_dependent DNA replication 55 Genes annotated by the GO term GO:0006261. The process
whereby new strands of DNA are synthesized, using parental
DNA as a template for the DNA-dependent DNA polymerases
that synthesize the new strands.
2 0.0364 4.39E-02
Structure specific DNA binding 55 Genes annotated by the GO term GO:0043566. Interacting
selectively with DNA of a specific structure or configuration
e.g. triplex DNA binding or bent DNA binding.
2 0.0364 4.39E-02
Sequence specific DNA binding 57 Genes annotated by the GO term GO:0043565. Interacting
selectively with DNA of a specific nucleotide composition,
e.g. GC-rich DNA binding, or with a specific sequence motif
or type of DNA e.g. promotor binding or rDNA binding.
2 0.0351 4.68E-02
doi:10.1371/journal.pone.0031283.t004
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expression level of 18,400 transcripts and variants (approximately
11,000 genes). The preparation of cRNA hybridization, signal
scanning, data acquisition, and preliminary analysis were
performed at the National Engineering Center for Biochip at
Shanghai according to the standard protocols recommended by
Affymetrix (Affymetrix, Santa Clara, CA, USA). Raw data
generated from affymetrix Human U133Plus2.0 were processed
and normalized by RMA method with Gene Spring Software 11.0
(Agilent technologies, Santa Clara, CA, US), then the values were
log2 transformed. Differential gene analysis was preliminarily
performed using Welch t test and then P value adjustment under
multiple hypothesis testing was implemented with multtest
package in Bioconductor under the adjustment method of
Bonferroni. We used Welch t test and boost strap resampling
approach (B=100,000) to compute t statistics and p values. The
threshold for differential expressed genes (DEGs) was chosen as
0.01.
All data is MIAME compliant and that the raw data has been
deposited in a MIAME compliant database (E.g. ArrayExpress,
GEO), as detailed on the MGED Society website http://www.
mged.org/Workgroups/MIAME/miame.html. The accession
numbers is GSE32280.
Disease model and classification
To select the smallest size of biomarkers with robust predictive
power and fewer potential false positives, more stringent thresholds
were used to identify genes with even greater reliability. Firstly, the
thresholds for differentially expressed SSD and MDD signatures
compared to control and differentially expressed signatures
between SSD and MDD were set as 1.0E-4, 5.0E-4 and 1.0E-4
respectively. Alternatively, P values in combination with fold-
change values were used to identify potential biomarker genes to
limit the likelihood of false positive results. Secondly, these
signatures from 3 pair-wise comparisons were ranked according
to their adjusted P values and the top N signatures were merged
directly (to obtain a small size of biomarkers comparatively and a
better classification performance, the top 10, 15, 18, 20, 25 and 30
signatures from each group were merged respectively). Then, we
applied SVM (Support vector machines) on each of candidate
expression profiles to search better combination of biomarkers
with robust prediction performances (accuracy, sensitivity or
specificity). Finally, leave-one-off method was used to validate
the biomarkers. Leave-one-off validation involves using a single
observation from the original sample as the validation data, and
the remaining observations as the training data. This was repeated
such that each observation in the sample was used once as the
validation data.
Gene Ontology Analysis
Standard methods for testing over-representation of a GO
category assume that, under the null hypothesis, each gene has
equal probability of being detected as DEG (differential expressed
gene) [47]. Under this assumption, the number of genes associated
with a category that overlap with the set of DEG follows a
hypergeometric distribution. Hence the GO test can be conducted
using Fisher’s exact test, which uses the hypergeometric distribu-
tion, or Pearson’s chi-square test, which is a computationally
convenient approximation.
Network and Pathway Analysis
Pathway was analysis using human pathways from KEGG,
biocarta, and metabolism pathway databases [48]. Scoring the
prioritation of network/pathways according to the relevance to
input data. In cases of SSD and MDD experiments result, we
analysis how different pathways and networks modules can be
prioritized based on their statistical significance with respect to
such experimental datasets. Significance is evaluated based on the
size of the intersection between differential expressed gene
signatures and set of genes/proteins corresponding to a network
module/pathway curated in pathway database. This problem can
be cast as selection without replacement and the probability to
randomly obtain intersection of certain size between differential
expressed gene signatures and a network/pathway follows
hypergeometric distribution When considering a set of DEG
signatures (I), invariable number r of DE signatures among the N
nodes of the pathway/network module. The probability of a subset
of size n to include r DE genes provided that n and R are
unrelated (null-hypothesis) follows the hypergeometric distribu-
tion.
Multiclass SVM implementation
In order to classify SSD and MDD from healthy control
simultaneously, support vector machines (SVMs) was utilized for
training and testing on candidate signature expression profiles
from signature selection step. SVMs which represents an extension
to nonlinear models of the generalized portrait algorithm
Table 5. Demographic data for patients and healthy controls.
Group Age (years) Gender Course of disease(months)
SSD
12 5 M 3 . 0
22 7 M 5 . 0
32 7 M 2 . 5
43 6 M 3 . 0
5 29 F 3.25
6 30 F 1.75
73 5 F 3 . 5
84 1 F 2 . 0
MDD
12 4 M 3 . 3
22 6 M 5 . 3
32 7 M 2 . 5
43 8 M 3 . 0
52 8 F 3 . 5
63 1 F 1 . 5
73 5 F 3 . 0
8 41 F 2.25
HC
12 4 M -
22 9 M -
32 7 M -
43 7 M -
52 8 F -
63 0 F -
73 5 F -
84 1 F -
MDD: Major depression disorder; SSD: Subsyndromal symptomatic depression;
HC: Healthy controls.
doi:10.1371/journal.pone.0031283.t005
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methods that can be applied to classification or regression [49].
The SVM takes a set of input data, and predicts, for each given
input, which of two possible classes the input is a member of,
which makes the SVM a non-probabilistic binary linear classifier.
Since an SVM is a classifier, then given a set of training examples,
each marked as belonging to one of two categories, an SVM
training algorithm builds a model that predicts whether a new
example falls into one category or the other.
The original SSD, MDD and control problem may be stated in
a finite dimensional space, but it often happens that in that space
the sets to be discriminated are not linearly separable. For this
reason it was proposed that the original finite dimensional space be
mapped into a much higher dimensional space presumably
making the separation easier in that space. In order to clearly
classify SSD and MDD from controls, multiclass SVM were also
used in aims to assign labels to instances by using support vector
machines. The multiclass approach for conducting this is to reduce
the single multiclass problem into multiple binary classification
problems. Each of the problems yields a binary classifier, which is
assumed to produce an output function that gives relatively large
values. In end, polynomial kernel was applied with the best
predictive performances for combinatorial gene signatures from
the three groups.
De novo cis-Regulatory element analysis
Cis-regulatory motifs are essential elements for gene transcrip-
tion [50]. We also interrogated the over-representative motifs on
promoter sequences collected from UCSC (www.genome.ucsc.
edu/). Two thousand bps sequences around TSS for SSD and
MDD signatures and biomarkers for classifying three groups
(MDD, SSD and controls, together) were all considered for in
promoter-based de novo motif analysis.
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